Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AFRINOL is an oral extended-release tablet containing pseudoephedrine sulfate, a sympathomimetic decongestant. It is indicated for nasal congestion relief associated with upper respiratory infections, sinusitis, and allergic rhinitis. The drug works by stimulating alpha-adrenergic receptors to reduce swelling of nasal mucosa and improve airway patency.
Product is in late-stage lifecycle with moderate competitive pressure (30); teams should prepare for transition planning and line extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Working on AFRINOL offers career value primarily in mature product stewardship, cost management, and transition planning rather than growth acceleration. Professionals should expect focus on defending market share, optimizing margins, and preparing the organization for LOE.
Worked on AFRINOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.